FDA decision on Duratech expected on March 17 (Nasdaq:OSTE)
Duratech™ BioRegeneration Matrix is a medical device that has been devekioed by Osteotech, Inc (Nasdaq:OSTE). Now the company wants to bring this product into the market. However, it needs the approval from the United States of America’s toughest regulator – the Food and Drug Administration (FDA).
Continue reading...FDA meeting on BEMA Granisetron due on March 17 (Nasdaq:BDSI)
11 March 2010
Comments Off
BEMA Granisetron is a product candidate that has been developed by BioDelivery Services International, Inc. (Nasdaq:BDSI). According to the company, this product can reduce vomiting and nausea.
Continue reading...PDUFA date for Exenatide Approaching (Nasdaq:AMLN), (NYSE:LLY)
11 March 2010
Comments Off
Exenatide is a drug that has been co-developed by Amylin Pharmaceuticals, Inc, (Nasdaq:AMLN), Alkermes, Inc. (Nasdaq: ALKS) and Eli Lilly and Company (NYSE:LLY). Exenatide is currently available in the market as BYETTA® injections. However, now the three companies want to use exenatide as a drug given once per week to treat people suffering from type [...]
Continue reading...Intermune’s Meeting with FDA expected (Nasdaq:ITMN)
11 March 2010
Comments Off
Pirfenidone is a drug that has been developed by Intermune, Inc. (Nasdaq:ITMN). According to the company, this drug can be used to treat patients suffering from idiopathic pulmonary fibriosis (IPF) by keeping the lungs healthy.
Continue reading...Additional results for Picoplatin’s Phase 2 trial anticipated (Nasdaq:PARD)
8 March 2010
Comments Off
Picoplatin is a type of cancer drug developed by Poniard Pharmaceuticals, Inc. (Nasdaq:PARD). On January 7, 2010, the company announced that it wanted to form a strategic partnership so that it could continue develop picoplatin for treating “solid tumor malignanciesâ€.
Continue reading...FDA decision on Dacogen expected March 8 (NYSE: ESALY.PK)
8 March 2010
Comments Off
Eisai Co., Ltd. is a corporation that is operating in several countries across the world. It has a number of companies in the United States of America, too, such as Morphotek, Inc. (which sells specialized antibodies for the treatment of monoclonal diseases), Eisai Research Institute of Boston, Inc. (that discovers novel organic chemicals) and Eisai [...]
Continue reading...FDA decision for NexMed expected (Nasdaq:NEXM)
8 March 2010
Comments Off
NexMed, Inc. (Nasdaq:NEXM) is a specialty contract research organization – also called clinical research organization (CRO). It has decades’ experience of providing “in vitro and in vivo pharmacology services and research modelsâ€.
Continue reading...PDUFA date for Exalgo is approaching (NASDAQ:CRXX)
2 March 2010
Comments Off
CombinatoRx, Incorporated (NASDAQ:CRXX) and Neuromed Pharmaceuticals Inc., two companies which have merged into one on June 30, 2009, have developed a drug called Exalgoâ„¢ (the brand name for hydromorphone HCl).
Continue reading...FDA’s decision on Excellagen expected March 3rd (NYSE Amex:CXM)
2 March 2010
Comments Off
Tissue Repair Company is a subsidiary of Cardium Therapeutics, Inc. (NYSE Amex:CXM). The former already submitted a 510(K) premarket notification application to the United States of America’s Food & Drug Administration (FDA).
Continue reading...FDA’s review of Belacept expected soon (NYSE:BMY)
2 March 2010
Comments Off
Belacept is a pharmaceutical agent that is being developed by the Brystol-Myers Squibb Company (NYSE:BMY), often called Brystol-Myers for short.
Continue reading...
11 March 2010
Comments Off